Skip to main content
CVE:HVT

Harvest One Cannabis Competitors

C$0.08
0.00 (0.00 %)
(As of 05/14/2021 03:53 PM ET)
Add
Compare
Today's Range
C$0.08
C$0.09
50-Day Range
C$0.09
C$0.13
52-Week Range
C$0.05
C$0.58
Volume288,941 shs
Average Volume1.25 million shs
Market CapitalizationC$21.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Harvest One Cannabis (CVE:HVT) Vs. FLWR, ASP, RX, CPH, MDP, and VIR

Should you be buying HVT stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Harvest One Cannabis, including The Flowr (FLWR), Acerus Pharmaceuticals (ASP), BioSyent (RX), Cipher Pharmaceuticals (CPH), Medexus Pharmaceuticals (MDP), and Viridium Pacific Group (VIR).

The Flowr (CVE:FLWR) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for The Flowr and Harvest One Cannabis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr0000N/A
Harvest One Cannabis0000N/A

The Flowr presently has a consensus price target of C$0.88, indicating a potential upside of 260.54%. Given The Flowr's higher probable upside, equities analysts plainly believe The Flowr is more favorable than Harvest One Cannabis.

Profitability

This table compares The Flowr and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Earnings and Valuation

This table compares The Flowr and Harvest One Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrC$7.51 million11.80C$-343,678,650.00C($0.95)-0.26
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24

Harvest One Cannabis has higher revenue and earnings than The Flowr. The Flowr is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Harvest One Cannabis beats The Flowr on 4 of the 6 factors compared between the two stocks.

Acerus Pharmaceuticals (TSE:ASP) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Acerus Pharmaceuticals and Harvest One Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acerus Pharmaceuticals0000N/A
Harvest One Cannabis0000N/A

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Harvest One Cannabis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acerus PharmaceuticalsC$1.09 million63.77C$-55,353,168.00C($0.04)-1.25
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24

Acerus Pharmaceuticals has higher earnings, but lower revenue than Harvest One Cannabis. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acerus Pharmaceuticals and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acerus PharmaceuticalsN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Summary

Acerus Pharmaceuticals beats Harvest One Cannabis on 3 of the 5 factors compared between the two stocks.

BioSyent (CVE:RX) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares BioSyent and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSyentN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for BioSyent and Harvest One Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSyent02002.00
Harvest One Cannabis0000N/A

BioSyent currently has a consensus price target of C$7.00, suggesting a potential downside of 7.65%. Given BioSyent's higher probable upside, equities analysts plainly believe BioSyent is more favorable than Harvest One Cannabis.

Earnings & Valuation

This table compares BioSyent and Harvest One Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSyentC$22.33 million4.31C$3.68 millionC$0.2926.14
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24

BioSyent has higher revenue and earnings than Harvest One Cannabis. Harvest One Cannabis is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Summary

BioSyent beats Harvest One Cannabis on 6 of the 6 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Harvest One Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cipher PharmaceuticalsC$21.61 million1.76C$5.42 millionC$0.207.01
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24

Cipher Pharmaceuticals has higher revenue and earnings than Harvest One Cannabis. Harvest One Cannabis is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cipher PharmaceuticalsN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Cipher Pharmaceuticals and Harvest One Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cipher Pharmaceuticals00103.00
Harvest One Cannabis0000N/A

Summary

Cipher Pharmaceuticals beats Harvest One Cannabis on 5 of the 6 factors compared between the two stocks.

Medexus Pharmaceuticals (CVE:MDP) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Valuation & Earnings

This table compares Medexus Pharmaceuticals and Harvest One Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.26C$-34,573,801.00C($1.81)-3.93
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24

Medexus Pharmaceuticals has higher revenue and earnings than Harvest One Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Medexus Pharmaceuticals and Harvest One Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
Harvest One Cannabis0000N/A

Profitability

This table compares Medexus Pharmaceuticals and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Harvest One Cannabis (CVE:HVT) and Viridium Pacific Group (CVE:VIR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Harvest One Cannabis and Viridium Pacific Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harvest One Cannabis0000N/A
Viridium Pacific Group0000N/A

Profitability

This table compares Harvest One Cannabis and Viridium Pacific Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harvest One CannabisN/AN/AN/A
Viridium Pacific GroupN/AN/AN/A

Earnings & Valuation

This table compares Harvest One Cannabis and Viridium Pacific Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harvest One CannabisC$8.50 million2.52C$-89,908,156.00C($0.36)-0.24
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97

Viridium Pacific Group has lower revenue, but higher earnings than Harvest One Cannabis. Viridium Pacific Group is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Viridium Pacific Group beats Harvest One Cannabis on 3 of the 5 factors compared between the two stocks.


Harvest One Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FLWR
The Flowr
1.0$0.25flatC$70.01 millionC$7.51 million-0.26Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05flatC$69.19 millionC$1.09 million-1.25Gap Down
RX
BioSyent
0.8$7.58flatC$64.81 millionC$22.33 million26.14
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.41flatC$43.16 millionC$21.61 million7.01Gap Down
MDP
Medexus Pharmaceuticals
0.6$7.12flatC$38.66 millionC$108.29 million-3.93
VIR
Viridium Pacific Group
0.7$0.38flatC$37.54 millionC$1.09 million-2.97Gap Up
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29flatC$36.73 millionN/A-2.61News Coverage
Gap Down
IN
InMed Pharmaceuticals
0.6$4.19flatC$33.73 millionN/A-2.40
NDVA
Indiva
1.3$0.43flatC$27.54 millionC$7.92 million-3.32
EVE
Eve & Co Incorporated
1.0$0.26flatC$21.32 millionC$2.84 million-0.80
SUGR
SugarBud Craft Growers
0.7$0.05flatC$11.81 millionC$66,906.00-0.03
NU
NeutriSci International
0.5$0.17flatC$8.65 millionC$74,572.00-12.14
AQS
Aequus Pharmaceuticals
0.9$0.15flatC$6.03 millionC$2.59 million-13.64
LBL
Lattice Biologics
0.5$0.04flatC$4.67 millionC$2.24 million-2.22
THCX
(THCX.V)
0.6$5.30flatC$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5$30.80flatC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Up
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.